Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xilio Therapeutics ( (XLO) ) has shared an update.
On August 22, 2025, Xilio Therapeutics, Inc. received a deficiency letter from Nasdaq indicating non-compliance with the $10 million stockholders’ equity requirement for continued listing on The Nasdaq Global Select Market, as the company reported $7,069,000 in equity for the quarter ended June 30, 2025. The company has until October 6, 2025, to submit a compliance plan, with potential extensions or a transfer to The Nasdaq Capital Market as possible outcomes. Previously, on April 4, 2025, Xilio was also notified of failing to meet the $1.00 minimum bid price requirement, with the initial compliance period ending on October 1, 2025, and a potential additional period available. The company is exploring options to regain compliance.
The most recent analyst rating on (XLO) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Average Trading Volume: 578,274
Technical Sentiment Signal: Sell
Current Market Cap: $36.28M
See more data about XLO stock on TipRanks’ Stock Analysis page.